Navigation Links
Talyst and RXinnovate Partner on Pharmacy Automation Implementation
Date:10/1/2009

BELLEVUE, Wash., Oct. 1 /PRNewswire/ -- Talyst, a leader in pharmacy automation systems, announced today a partnership with RXinnovate, a healthcare consultancy, to offer top-of-the-line implementation services to Talyst's clients in the acute care industry. Talyst recognizes that every hospital is unique and requires a tailored approach that addresses its size, technology, floor plan and workflow.

By partnering with RXinnovate, Talyst is able to broaden its implementation team to include more pharmacists with hands-on implementation experience. RXinnovate will work with Talyst to plan, direct, and facilitate successful implementations. "We have enjoyed a working relationship with RXinnovate for almost a year," said Carla Corkern, Talyst CEO and chairman of the board. "They have proven their ability to ensure the smooth implementation of our products in acute care settings. It's great to make the relationship official. "

RXinnovate is a respected healthcare consultancy with more than 10 years of broad-based experience in acute care hospitals. It has a wide range of technological expertise that encompasses Talyst products and those from healthcare technology providers that interface with Talyst solutions. Its implementation team includes pharmacists with proficiency in information systems configuration, pharmacy wholesale, and legacy hardware.

For further information, please visit www.Talyst.com or www.RXinnovate.com.

About Talyst

Talyst is engineering the safer pharmacy. The company was founded in 2002 to provide easy-to-use, automated medication management systems to acute care hospital pharmacies. The following year, Talyst launched AutoPharm®, the innovative software platform designed to integrate medication storage, inventory, ordering, barcoding, and clinical systems.

By 2009, Talyst had installed automated systems in close to 400 acute care hospitals and integrated healthcare companies. By leveraging our expertise in acute care pharmacy automation, we are now building unique systems designed specifically to meet the needs of long-term care facilities and correctional institutions. Talyst is dedicated to delivering world-class software and proven hardware components to enhance efficiency, provide greater inventory control, and improve patient safety in all environments. For more information, see www.talyst.com or call 877-4-Talyst (877-482-5978).

About RXinnovate

RXinnovate Consulting was founded in 1999 to provide a broad range of consulting services to hospitals and health systems across the country. Our consulting and implementation teams have over 20 years experience in pharmacy management and the skill sets for designing and implementing major patient care projects for hospitals. RXinnovate's comprehensive consulting portfolio is designed to meet the unique challenges facing hospitals and healthcare systems.

SOURCE Talyst


'/>"/>
SOURCE Talyst
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction
2. Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2007 Financial Results
3. Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia
4. Catalyst Pharmaceutical Partners, Inc. Begins Enrollment for U.S. Phase II Clinical Trial of CPP-109 in Patients with Methamphetamine Addiction
5. Catalyst Pharmaceutical Partners Announces Publication of Animal Data Demonstrating Vigabatrin Effective for Weight Loss
6. Catalyst Reaches Enrollment Target for its U.S. Phase II Cocaine Trial
7. Catalyst Pharmaceutical Partners Announces Top-Line Results of CPP-109 Phase II Trial for Cocaine Addiction
8. Catalyst Pharmaceutical Partners Continues Clinical Development of CPP-109 For The Treatment of Cocaine and Methamphetamine Addiction
9. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
10. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
11. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/28/2017)... , Sept. 28, 2017 Hill-Rom Holdings, Inc. ... earnings conference call and webcast on Friday, November 3, ... (EDT) and ending at approximately 8:30 a.m. (CDT) / ... the company,s 2017 financial performance and guidance for 2018, ... initiatives to enhance operational performance, and long-range financial outlook ...
(Date:9/27/2017)... and NEW YORK , Sept. 27, 2017  DarioHealth ... and big data solutions, today announced that its MyDario product is expected ... local TV listings for when The Dr. Oz Show airs in your ... The nine-time Emmy ... ...
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 ... characterized by frequent cessation in breathing. Oral appliances can offer significant relief to ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has ... today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula ... the highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, ...
(Date:10/12/2017)... MD (PRWEB) , ... October 12, 2017 , ... The ... of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual ... – 8. , In honor of Morris F. Collen, a pioneer in the field ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: , ... to enable prevention of a major side effect of chemotherapy in children. Cisplatin ... patients. For cisplatin, hearing loss is FDA listed on-label as a dose limiting ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a ... of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners ... October 11, 2017. , The annual award competition recognizes editorial and design excellence across ...
Breaking Medicine News(10 mins):